名臣健康(002919) - 2024 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2024 was CNY 361,783,077.71, representing a decrease of 11.06% compared to CNY 406,772,539.06 in the same period last year[5] - Net profit attributable to shareholders increased by 31.34% to CNY 44,792,608.81 from CNY 34,104,153.62 year-on-year[5] - Basic and diluted earnings per share rose by 33.33% to CNY 0.20 from CNY 0.15 in the previous year[5] - Total operating revenue for Q1 2024 was CNY 361,783,077.71, a decrease of 11.06% from CNY 406,772,539.06 in Q1 2023[21] - Net profit for Q1 2024 was CNY 44,792,608.81, an increase of 31.4% compared to CNY 34,104,153.62 in Q1 2023[22] Cash Flow - The net cash flow from operating activities improved by 48.13%, reaching CNY -30,954,318.55, compared to CNY -59,671,619.97 in Q1 2023[11] - Cash inflow from operating activities totaled CNY 284,521,640.80, down from CNY 399,260,552.94 in Q1 2023[24] - The net cash flow from operating activities for Q1 2024 was -30,954,318.55, an improvement from -59,671,619.97 in Q1 2023, indicating a 48% reduction in cash outflow[26] - Total cash outflow from operating activities amounted to 315,475,959.35, down from 458,932,172.91 in the previous year, reflecting a decrease of approximately 31%[26] - The net cash flow from investment activities was -22,174,153.25, compared to -2,100,092.89 in the same period last year, indicating a decline in investment performance[26] Assets and Liabilities - Total assets at the end of Q1 2024 were CNY 1,271,968,665.67, a slight decrease of 0.16% from CNY 1,274,031,659.57 at the end of the previous year[5] - Total liabilities decreased to CNY 417,289,759.61 from CNY 464,145,362.32, reflecting a reduction of 10.08%[22] - The company reported a total of ¥387,051,097.52 in non-current assets, down from ¥416,452,715.59[18] Shareholder Information - Total number of common shareholders at the end of the reporting period is 11,632[14] - The largest shareholder, Chen Qinfang, holds 35.01% of shares, totaling 77,782,170 shares, with 5,620,000 shares pledged[14] - The total number of preferred shareholders is zero, indicating no preferred shares outstanding[16] Expenses - Research and development expenses decreased by 37.84% to CNY 19,631,760.74 from CNY 31,582,395.46 in the same period last year[10] - Total operating costs decreased to CNY 306,836,632.03, down 19.21% from CNY 379,638,664.04 in the previous year[21] - Sales expenses decreased to CNY 136,956,978.81, down 14.26% from CNY 159,736,843.38 in the previous year[22] Other Financial Metrics - The company recorded a 1984.11% increase in asset disposal gains to CNY 811,417.52 compared to CNY -43,066.42 in the same period last year[10] - The company reported a significant increase in financial expenses by 73,122.10% due to reduced exchange gains[10] Cash and Equivalents - The company's cash and cash equivalents decreased to ¥110,179,597.00 from ¥169,035,036.07[17] - Cash and cash equivalents at the end of Q1 2024 stood at 110,179,597.00, up from 68,987,820.59 at the end of Q1 2023, representing a 60% increase[26] Accounting and Audit - The company has not yet adopted the new accounting standards for the current fiscal year[27] - The Q1 2024 report was not audited, indicating that the figures may be subject to change upon final audit[28] Market and Product Development - The company has not disclosed any new product developments or market expansion strategies in the current report[15]